Physician
Optum Medical Care, P.C.
Optum Medical Care, P.C. was paid $105.26M by Medicaid between Jan 2018 and Dec 2024, across 368 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 33% of everything it billed.
33Billing provider infoOPTUM MEDICAL CARE, P.C.
MOUNT KISCO, NY 10549
MOUNT KISCO, NY 10549
33aNPI1982643003assigned 06/05/2006
33bProvider typeHematology & Oncology Physician
28Total paid$105.26M
24GClaims1,342,057
24DCodes billed368
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Hematology & Oncology Physician providers in New York
Rank by total paid#1 of 441
Median peer was paid$9K
This provider vs. median11,116×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 36,615 | $2.79M | |
| 2019 | 72,455 | $4.89M | |
| 2020 | 107,499 | $7.26M | |
| 2021 | 157,886 | $12.95M | |
| 2022 | 269,549 | $22.42M | |
| 2023 | 406,657 | $32.87M | |
| 2024incomplete | 291,396 | $22.09M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 33% | 290,515 | 274,929 | $34.38M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 15% | 95,086 | 91,023 | $15.91M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 2.9% | 13,972 | 13,842 | $3.06M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 2.5% | 16,849 | 16,830 | $2.62M |
| 76641 | 2.4% | 11,937 | 11,806 | $2.57M | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 2.4% | 13,526 | 13,521 | $2.48M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.9% | 9,299 | 9,280 | $2.05M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1.8% | 13,630 | 13,624 | $1.90M |
| 87631 | 1.8% | 10,905 | 10,735 | $1.88M | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.6% | 12,176 | 12,163 | $1.72M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.4% | 15,922 | 15,115 | $1.46M |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 1.3% | 74,488 | 73,651 | $1.36M |
356 more codes
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1.3% | 8,048 | $1.34M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.2% | 10,396 | $1.31M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.2% | 23,097 | $1.31M |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 1.1% | 7,806 | $1.17M |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 2,611 | $1.04M |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 6,381 | $972K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 12,951 | $961K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 6,006 | $944K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 27,286 | $883K |
| 92060 | <1% | 11,146 | $869K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 6,529 | $831K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 18,556 | $764K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 18,545 | $764K |
| 31231 | <1% | 2,389 | $667K | |
| 76830 | Ultrasound, transvaginal | <1% | 3,614 | $628K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 11,249 | $589K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 3,354 | $530K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 7,198 | $508K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 11,601 | $482K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 2,027 | $478K |
| A4550 | Surgical trays | <1% | 1,942 | $464K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 3,549 | $450K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 2,371 | $446K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 10,047 | $415K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 4,468 | $387K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,315 | $375K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,120 | $361K |
| 76536 | <1% | 2,455 | $360K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,414 | $354K |
| 81513 | <1% | 4,265 | $349K | |
| 88174 | <1% | 11,928 | $349K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,234 | $348K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 8,503 | $344K |
| 76813 | <1% | 1,985 | $343K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,739 | $334K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 2,747 | $334K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,320 | $330K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,120 | $270K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 8,930 | $267K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 2,245 | $241K |
| 76801 | <1% | 1,379 | $234K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 24,684 | $234K |
| 92250 | <1% | 6,198 | $227K | |
| 74183 | <1% | 547 | $224K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 867 | $204K |
| 77065 | Tomosynthesis, mammo | <1% | 1,143 | $204K |
| 80053 | Comprehensive metabolic panel | <1% | 15,407 | $204K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 503 | $202K |
| 72197 | <1% | 401 | $179K | |
| 99205 | Prolong outpt/office vis | <1% | 603 | $179K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 1,196 | $178K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 1,154 | $178K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 887 | $175K |
| 17110 | <1% | 1,101 | $172K | |
| 87428 | <1% | 3,874 | $171K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 618 | $168K |
| 92557 | <1% | 3,478 | $167K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 960 | $164K |
| 73630 | <1% | 3,377 | $158K | |
| 80061 | Lipid panel | <1% | 10,548 | $155K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,403 | $153K |
| 92567 | <1% | 6,782 | $152K | |
| 87481 | <1% | 4,280 | $151K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 563 | $149K |
| 92551 | <1% | 20,625 | $146K | |
| 77066 | Tomosynthesis, mammo | <1% | 650 | $142K |
| 92015 | Determination of refractive state | <1% | 10,568 | $139K |
| 95117 | <1% | 7,677 | $131K | |
| 92134 | <1% | 2,413 | $122K | |
| 73562 | <1% | 2,070 | $113K | |
| 75574 | <1% | 342 | $106K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 812 | $105K |
| 76770 | <1% | 709 | $103K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,515 | $102K |
| 90461 | <1% | 5,627 | $102K | |
| 59426 | <1% | 1,063 | $100K | |
| 19083 | <1% | 130 | $99K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,224 | $95K |
| 00731 | <1% | 398 | $94K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 72 | $93K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 10,106 | $90K |
| 93000 | <1% | 4,344 | $89K | |
| 96127 | <1% | 18,221 | $89K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 12,424 | $88K |
| 71250 | <1% | 566 | $87K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 2,602 | $80K |
| 84439 | <1% | 7,421 | $78K | |
| 92588 | <1% | 1,892 | $75K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 592 | $74K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 138 | $72K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 132 | $67K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,200 | $67K |
| 80050 | General health panel | <1% | 1,897 | $66K |
| 76642 | <1% | 585 | $66K | |
| 73610 | <1% | 1,257 | $63K | |
| 72100 | <1% | 1,176 | $62K | |
| 77080 | <1% | 1,250 | $61K | |
| 92082 | <1% | 1,147 | $60K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 71,037 | $60K |
| 92552 | <1% | 1,130 | $56K | |
| 73030 | <1% | 1,280 | $56K | |
| 41010 | <1% | 159 | $51K | |
| 82728 | <1% | 2,789 | $47K | |
| 73130 | <1% | 882 | $46K | |
| 73221 | <1% | 159 | $42K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,200 | $42K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 2,320 | $41K |
| 70486 | <1% | 234 | $41K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 102 | $40K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 537 | $40K |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 298 | $39K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,349 | $39K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,114 | $37K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 305 | $36K |
| 92587 | <1% | 2,107 | $35K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 148 | $35K |
| 00811 | <1% | 168 | $35K | |
| 77072 | <1% | 792 | $29K | |
| 99385 | <1% | 166 | $29K | |
| 72141 | <1% | 114 | $27K | |
| 77062 | <1% | 341 | $26K | |
| 88342 | <1% | 130 | $25K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 214 | $25K |
| 82607 | <1% | 1,681 | $24K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,631 | $24K |
| 90686 | <1% | 16,211 | $24K | |
| 81003 | <1% | 12,472 | $24K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 199 | $24K |
| 31575 | <1% | 121 | $23K | |
| 94010 | <1% | 739 | $23K | |
| 88142 | <1% | 960 | $23K | |
| 99459 | <1% | 732 | $23K | |
| 88141 | <1% | 661 | $22K | |
| 83550 | <1% | 1,992 | $21K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,751 | $21K |
| 99051 | <1% | 2,491 | $21K | |
| 00142 | <1% | 173 | $21K | |
| 73620 | <1% | 487 | $20K | |
| 86769 | <1% | 374 | $20K | |
| 81002 | <1% | 4,708 | $20K | |
| 74178 | <1% | 42 | $20K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 54 | $20K |
| 81025 | <1% | 2,330 | $19K | |
| 72040 | <1% | 358 | $18K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 57 | $18K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 184 | $17K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 1,772 | $17K |
| 20610 | <1% | 192 | $17K | |
| 69210 | <1% | 356 | $17K | |
| 99173 | <1% | 20,998 | $17K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 37 | $16K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,526 | $14K |
| 0001A | <1% | 259 | $14K | |
| 0002A | <1% | 257 | $14K | |
| 00812 | <1% | 67 | $14K | |
| 92568 | <1% | 808 | $13K | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 66 | $13K |
| 73110 | <1% | 253 | $13K | |
| 72110 | <1% | 203 | $13K | |
| 86803 | <1% | 795 | $13K | |
| S9083 | Global fee urgent care centers | <1% | 39 | $12K |
| 90674 | <1% | 4,506 | $12K | |
| 83540 | <1% | 1,476 | $12K | |
| 93970 | <1% | 50 | $11K | |
| 99188 | <1% | 786 | $11K | |
| 94664 | <1% | 541 | $11K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 75 | $10K |
| 86140 | <1% | 1,470 | $9K | |
| 97035 | <1% | 535 | $9K | |
| 95886 | <1% | 39 | $9K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 411 | $9K |
| 73502 | <1% | 148 | $9K | |
| 92201 | <1% | 282 | $9K | |
| 77061 | <1% | 157 | $9K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 190 | $8K |
| 88312 | <1% | 41 | $8K | |
| 99177 | <1% | 3,239 | $8K | |
| 92202 | <1% | 454 | $8K | |
| 72050 | <1% | 109 | $8K | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 143 | $8K |
| 88304 | <1% | 109 | $8K | |
| 99223 | Prolong inpt eval add15 m | <1% | 43 | $8K |
| 87486 | <1% | 164 | $7K | |
| 87581 | <1% | 164 | $7K | |
| 87340 | <1% | 608 | $7K | |
| 0012A | <1% | 154 | $7K | |
| 0011A | <1% | 154 | $7K | |
| 94375 | <1% | 141 | $7K | |
| 77049 | <1% | 13 | $7K | |
| G0268 | Removal of impacted cerumen (one or both ears) by physician on same date of service as audiologic function testing | <1% | 264 | $7K |
| 51798 | <1% | 515 | $7K | |
| 99417 | Prolong home eval add 15m | <1% | 69 | $7K |
| 93015 | <1% | 70 | $7K | |
| 86618 | <1% | 333 | $7K | |
| 94729 | <1% | 79 | $7K | |
| 99401 | <1% | 288 | $7K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 27 | $6K |
| 92083 | <1% | 69 | $6K | |
| 0071A | <1% | 101 | $6K | |
| 92550 | <1% | 409 | $6K | |
| 0064A | <1% | 105 | $5K | |
| 58340 | <1% | 13 | $5K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 34 | $5K |
| 97162 | <1% | 51 | $5K | |
| 99386 | <1% | 25 | $5K | |
| 85652 | <1% | 1,488 | $5K | |
| 90661 | <1% | 1,877 | $5K | |
| 73564 | <1% | 79 | $5K | |
| 93971 | <1% | 28 | $5K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,350 | $4K |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 654 | $4K |
| 0072A | <1% | 78 | $4K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 41 | $4K |
| 94060 | <1% | 68 | $4K | |
| 94727 | <1% | 68 | $4K | |
| 00813 | <1% | 17 | $4K | |
| 92285 | <1% | 309 | $4K | |
| 81001 | <1% | 1,038 | $4K | |
| 82550 | <1% | 477 | $4K | |
| 72070 | <1% | 88 | $4K | |
| 92504 | <1% | 146 | $4K | |
| 88112 | <1% | 39 | $4K | |
| 87081 | <1% | 701 | $4K | |
| 11102 | <1% | 25 | $4K | |
| 87807 | <1% | 440 | $3K | |
| 01936 | <1% | 14 | $3K | |
| 97799 | <1% | 74 | $3K | |
| 86708 | <1% | 217 | $3K | |
| 0004A | <1% | 59 | $3K | |
| 73560 | <1% | 62 | $3K | |
| 82746 | <1% | 350 | $3K | |
| 0124A | <1% | 50 | $3K | |
| 01938 | <1% | 23 | $3K | |
| 90677 | <1% | 485 | $3K | |
| 97802 | <1% | 186 | $2K | |
| 86704 | <1% | 222 | $2K | |
| 74018 | <1% | 55 | $2K | |
| 86706 | <1% | 243 | $2K | |
| 3074F | <1% | 7,876 | $2K | |
| 84702 | <1% | 135 | $2K | |
| 99429 | <1% | 238 | $2K | |
| 88143 | <1% | 86 | $2K | |
| 87071 | <1% | 678 | $2K | |
| 83655 | <1% | 145 | $2K | |
| 92133 | <1% | 42 | $2K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 87 | $2K |
| 92579 | <1% | 40 | $2K | |
| 90715 | <1% | 276 | $2K | |
| 82977 | <1% | 217 | $2K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 186 | $2K |
| 83735 | <1% | 235 | $2K | |
| 0240U | <1% | 20 | $2K | |
| 99201 | <1% | 26 | $2K | |
| 85018 | <1% | 860 | $2K | |
| 76514 | <1% | 134 | $2K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 437 | $2K |
| 90636 | <1% | 12 | $2K | |
| 99442 | <1% | 14 | $1K | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 154 | $1K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 21 | $1K |
| 85027 | <1% | 241 | $1K | |
| 85045 | <1% | 219 | $1K | |
| 3079F | <1% | 3,464 | $1K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 72 | $1K |
| 3078F | <1% | 5,283 | $1K | |
| 86141 | <1% | 66 | $1K | |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 17 | $994.25 |
| 97803 | <1% | 13 | $991.14 | |
| 95806 | <1% | 12 | $901.60 | |
| 86431 | <1% | 123 | $888.48 | |
| 82962 | <1% | 206 | $828.90 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 99 | $823.56 |
| 82670 | <1% | 25 | $771.12 | |
| 87184 | <1% | 144 | $755.67 | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 25 | $690.60 |
| 84436 | <1% | 190 | $673.14 | |
| 90480 | <1% | 26 | $660.00 | |
| 73600 | <1% | 14 | $658.34 | |
| 76857 | <1% | 12 | $639.81 | |
| 84153 | <1% | 29 | $610.59 | |
| 95251 | <1% | 12 | $581.88 | |
| 82043 | <1% | 87 | $574.57 | |
| 82465 | <1% | 102 | $553.83 | |
| 87625 | <1% | 26 | $545.79 | |
| 72220 | <1% | 12 | $529.41 | |
| 83001 | <1% | 25 | $512.88 | |
| 94667 | <1% | 41 | $501.82 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 45 | $452.58 |
| 91322 | <1% | 13 | $437.76 | |
| 87186 | <1% | 41 | $424.56 | |
| 84480 | <1% | 47 | $411.87 | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 13 | $403.22 |
| 96161 | <1% | 179 | $401.27 | |
| 90656 | <1% | 787 | $398.32 | |
| 87077 | <1% | 41 | $398.26 | |
| 96380 | <1% | 26 | $358.31 | |
| 90474 | <1% | 55 | $355.00 | |
| 90619 | <1% | 415 | $351.91 | |
| 95024 | <1% | 14 | $333.32 | |
| 92558 | <1% | 26 | $314.26 | |
| 90651 | <1% | 189 | $306.26 | |
| 90670 | <1% | 1,977 | $303.45 | |
| 84550 | <1% | 51 | $297.48 | |
| 99406 | <1% | 13 | $277.84 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 13 | $258.84 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 146 | $254.96 |
| 87088 | <1% | 26 | $249.92 | |
| 85610 | <1% | 49 | $241.57 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 14 | $222.86 |
| 82570 | <1% | 28 | $180.80 | |
| 82950 | <1% | 26 | $161.18 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 14 | $136.22 |
| 90680 | <1% | 505 | $89.25 | |
| 98960 | <1% | 28 | $80.20 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 119 | $79.80 |
| 90698 | <1% | 306 | $71.40 | |
| 82272 | <1% | 12 | $66.79 | |
| J2704 | Injection, propofol, 10 mg | <1% | 22 | $54.41 |
| A4627 | Spacer, bag or reservoir, with or without mask, for use with metered dose inhaler | <1% | 66 | $53.32 |
| 85007 | <1% | 12 | $48.07 | |
| 87150 | <1% | 29 | $40.35 | |
| 94760 | <1% | 220 | $26.85 | |
| 3075F | <1% | 891 | $20.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 100 | $16.41 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 66 | $6.45 |
| 91306 | <1% | 70 | $0.01 | |
| 3077F | 0% | 665 | $0.00 | |
| 1124F | 0% | 572 | $0.00 | |
| 90633 | 0% | 141 | $0.00 | |
| 90734 | 0% | 255 | $0.00 | |
| 91300 | 0% | 418 | $0.00 | |
| 90707 | 0% | 25 | $0.00 | |
| 96160 | 0% | 98 | $0.00 | |
| 90685 | 0% | 38 | $0.00 | |
| 90710 | 0% | 26 | $0.00 | |
| 90672 | 0% | 16 | $0.00 | |
| 90621 | 0% | 12 | $0.00 | |
| 91312 | 0% | 34 | $0.00 | |
| 3008F | 0% | 2,037 | $0.00 | |
| 99000 | 0% | 11,125 | $0.00 | |
| 3044F | 0% | 494 | $0.00 | |
| 90723 | 0% | 514 | $0.00 | |
| 90647 | 0% | 371 | $0.00 | |
| 97010 | 0% | 549 | $0.00 | |
| 36416 | 0% | 1,846 | $0.00 | |
| 3080F | 0% | 460 | $0.00 | |
| 90744 | 0% | 58 | $0.00 | |
| 91301 | 0% | 241 | $0.00 | |
| 99050 | 0% | 77 | $0.00 | |
| 90660 | 0% | 13 | $0.00 | |
| 99070 | 0% | 27 | $0.00 | |
| 90696 | 0% | 13 | $0.00 | |
| 91307 | 0% | 277 | $0.00 | |
| 90697 | 0% | 25 | $0.00 | |
| 91305 | 0% | 14 | $0.00 | |
| 90620 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNASSER, JONATHAN (PRESIDENT OPTUM TRI STATE)